Who is sponsoring NCT03942185?

NCT03942185 is sponsored by Shanghai Yueyang Integrated Medicine Hospital.

What drugs are being tested in NCT03942185?

Interventions in NCT03942185: Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy, Oral Chinese Herbal Medicine according with syndrome differentiation therapy, Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy.

Is NCT03942185 still recruiting?

NCT03942185 is currently status unknown. Last updated 8 May 2019.

Last reviewed 2019-05-08 · How we verify

NCT03942185

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chinese Herbal Medicine for Psoriasis Vulgaris: a Real World Study

Status unknown Phase 2 Last updated 8 May 2019

What this trial tests

Phase 2 trial testing Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy in Psoriasis in 2,000 participants. Status unknown.

Timeline

1 June 2019

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Shanghai Yueyang Integrated Medicine Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	2,000
Start date	1 June 2019
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	20 locations across China

Drugs / interventions tested

Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy — full drug profile →
Oral Chinese Herbal Medicine according with syndrome differentiation therapy — full drug profile →
Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy — full drug profile →

Conditions studied

Psoriasis — all drugs for Psoriasis →

Sponsor

Shanghai Yueyang Integrated Medicine Hospital

Who can join

Adults 18 to 65, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to establish a multi-center clinical registration platform, to form the real world evidence of New Blood Syndrome Theory intervention in psoriasis, and to evaluate the therapeutic advantages of New Blood Syndrome Theory therapy in the clinical effective and recurrence rate of psoriasis vulgaris.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Characteristics of psoriasis vulgaris in China: a prospective cohort study protocol.
Luo Y, Ru Y, Sun X, Zhou Y, et al · · 2019 · cited 8× · PMID 31930095 · DOI 10.21037/atm.2019.10.46
Psoriasis complicated with metabolic disorder is associated with traditional Chinese medicine syndrome types: a hospital-based retrospective case-control study.
Sun X, Zhao H, Wang R, Li H, et al · · 2023 · cited 4× · PMID 36189747 · DOI 10.1080/03007995.2022.2129803

Verify or expand the search:

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Shanghai Yueyang Integrated Medicine Hospital trials

Trials by the same sponsor.

NCT07434076 — Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional · not yet recruiting
NCT07351448 — Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine · not yet recruiting
NCT07003386 — Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke · Phase 2, PHASE3 · recruiting
NCT06922565 — Efficacy of Acupuncture in the Treatment of Moderate-to-severe Atopic Dermatitis · NA · not yet recruiting
NCT06790940 — Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03942185 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Yueyang Integrated Medicine Hospital
Last refreshed: 8 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03942185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing